Exelixis, Inc. Overview
Pro stress-test →Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. The company is at an inflection point with its flagship product facing patent expiration in August 2026.
Strategic Profile
Pro stress-test →Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier stage pipeline forward. The company faces a critical transition period as it approaches an exclusivity cliff for cabozantinib, which currently accounts for 91% of total revenue.
Competitive Landscape
Pro stress-test →Exelixis competes in the oncology therapeutic space against major pharmaceutical companies developing targeted cancer therapies. Key competitors include companies with FDA-approved therapies for renal cell carcinoma, colorectal cancer, and other solid tumors. The company's competitive advantage lies in its cabozantinib franchise and emerging zanzalintinib pipeline, though it faces threats from generic competition and other TKI inhibitors.
Industry Context
Exelixis, Inc. operates in Biopharmaceutical / Oncology Therapeutics.
Key facts
Founded: 1994 · Headquarters: Alameda, US · Employees: 1,077 · Revenue: $2.32B · Market cap: $11.4B